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Chapter 1  
Scientific Background 
 
1.1 Human Primary Immunodeficiency Syndromes 
Primary immunodeficiency diseases (PIDs) represent a group of most 
heterogeneous syndromes characterized by development or functional defect of 
the Immune system.  More than 130 inherited conditions described 
immunodeficiencies exist (Chapel, H. 2003; Fischer, A. 2001; Buckley R. H. 
2000).  Clinical presentation is highly variable, ranging from various patterns of 
microbial susceptibility to allergy, lymphoproliferation or autoimmune 
manifestation the most of these syndromes are monogenic and lead to defects in 
any aspect of the immune response.  A great contribution to understanding the 
genetic basis of PIDs came up from recent report on using tools developed to 
study the human genome, approximately 100 genes associated to PIDs have 
been identified so far (Chapel, H. 2003; Fischer, A. 2001; Buckley R. H. 2000). 
Along with classical form in with there are clear sign of immune defect 
there are often several form in which the clinical features of immune defect are 
not completely clear so many cases are misdiagnosed.  In many cases, inherited 
diseases have led to the identification of new gene that are crucial in immune 
cell development or effector function, thus contributing to homeostatic 
mechanisms that keep the immune system in check to prevent overt autoimmune 
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disease.  In particular, in the last years the attention has been focused on the 
several form of ID in which an alteration of homeostatic mechanism is involved. 
The process which is involved in the control of immunological 
homeostasis named apoptosis or programmed cell death that exert its important 
role trough specialized cells.  These cells play their role of maintenance of the 
immune homeostasis through two principal mechanism: the secretory and non 
secretory pathway that will be illustrated below.   
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1.2 Apoptosis and the control of immune responses 
Apoptosis is a programmed cell death mechanism involved in normal cell 
turnover which can be induced by a variety of stimuli to eliminate damage, 
infected or useless cells.  Apoptosis is essential for the development of 
vertebrates, being involved in elimination of interdigital webs, palatogenesis, 
haematopoietic cell homeostasis and development of intestinal mucosa and 
retina (Denis F. et al 1998).  Apoptosis is caracterized morphologically by 
condensation of nuclear chromatin, internucleosomal cleavage of DNA, 
compaction of cytoplasmatic organelles, decrease in cell volume and loss of 
plasma membrane asymmetry resulting in recognition and phagocytosis (Denis 
F. et al 1998).  Inappropriate cell death plays a role in pathological condition 
such as cancer, autoimmunity and neurodegenerative diseases (Denis F. et al 
1998). 
Apoptosis plays a key role in the control of immune responce, infact, the 
majority of lymphocytes that in vivo expand and proliferate in response to 
foreign antigens, subsequently, will die to maintain a constant cell number. 
During the initial expansion phase of an immune response, growth factors and 
cytokines participate in the process, leading to T- and B-cell proliferation after 
encountering the antigens.  These agents, in a highly regulated fashion, are 
responsible for delivering cell signals that sustain the growth and survival of T 
cells.  At the end of an immune response apoptosis occurs to limit cell growth, 
thus restoring immunological homeostasis (Busiello R. et al 2004).  
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1.3 Mechanism of the apoptosis: Non secretory pathway and secretory 
pathway. 
During the last decade, major advances were made in understanding the 
complex regulatory mechanism of the cell concerning the control of its own 
death.  Several molecular pathways have been unraveled, and many proteins 
playing a role in these pathways have been described (Jutte van der Werff ten 
Bosh, Pediatr Drugs 2003).  Actually, it is common knowledge that the 
apoptosis is activated by non secretory and secretory pathways (Rieux- Laucat 
F. et al 2003). 
 In particular, the non secretory pathway functionally specialized 
membrane receptors.  These receptors, called death receptors, belong to TNF-
receptor (TNF-R)/NGF-receptor (NGF-R) superfamily which contain cysteine-
rich domains (CRDs) in the extracytoplasmic region.  The extracellular portion 
of these proteins is important for ligand binding.  Furthermore, these proteins 
are characterized by the presence of a functional domain named “death domain” 
(DD) in the cytoplasmic region, that binds the cytoplamic signaling proteins 
essential to induce apoptosis (Kischkel F.C. et al 1995).  Fas, also known as 
CD95 or Apo-1 or TNFRSF6 belongs to this family of proteins and is the most 
efficient inducer of apoptosis in the lymphocytes.  The molecule consists of 3 
extracellular CRDs and of 80 amino acid residues in the intracellular DD.  Fas 
ligand (FasL), molecule that belong to the TNF superfamily of the type II 
transmembrane proteins activate this receptor.  The intracellular and 
extracellular domains of FasL are located in the N- and C-terminal regions, 
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respectively.  The receptor-binding domain is located at the very end of the C-
terminus, and deletion of at least three amino acids from this region is sufficient 
to interfere with interactions with its receptor, Fas (Kavurma M.M. et al 2003).  
After ligand binding, three molecules of Fas assemble into complexes.  Fas 
signaling occurs through the interaction of Fas with the Fas Associated Death 
Domain (FADD), a cellular adaptor and, subsequently, with procaspases 8 
and/or 10 in a death inducing signaling complex (DISC) (Rieux-Laucat F. et al 
2003).  This complex serve to bring two or more caspase 8 precursors in close 
proximity, allowing for intermolecular autoproteolytic activation.  The active 
form of caspase 8 converted the procaspase 3 in caspase 3 (active enzyme) by 
proteolytic processing with a cascade model.  This effector caspase cleaved 
specific substrate inactivating or deregulating protein involved in DNA repair, 
mRNA splicing and DNA replication.   
Therefore the caspases contribute to apoptosis through disassembly of cell 
structures, they disintegrate the cell into apoptotic bodies and they induce the 
cell to display signals that mark it for phagocytosis (Thornberry et al 1998).(Fig. 
1)   
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Fig. 1: Non-secretory pathway 
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In the secretory or calcium-dependent pathway, cytotoxic T cells (CTLs) 
and Natural Killer cells (NK) are key effectors for the elimination of virus-
infected cells, and they deliver a lethal hit to their targets through involving a 
series of serine proteases called granzymes (Grz) and perforin (PRF1).   
PRF1 is present in granules of CTLs and NK cells.  Cytotoxic granules 
gather at site of contact between the CTL and the target cell, known as the 
immunological synapse.  The granule membrane fuses with the cell membrane 
and releases the contents of the granules in a process referred to as exocytosis.  
This results in rapid death of the target cell.  Secreted PRF1 inserts into the lipid 
bilayer thorough specific receptor, while the granzymes are potent activator of 
the caspases.  In fact they induce the cleavage of the caspases, including the 
caspase 3 (Darmon A. J. et al 1995).  The most recent model shows that the 
adhesion of the cytotoxic T lymphocytes to the target cell, via the interaction 
between the TCR and the antigen-MHC complex, triggers a Ca2+dependent 
degranulation process in the effector cells.  The degranulation process, causes 
the release of PRF1, which recognizes the mannose-6-phosphate receptor 
(MPR), thus leading to a macromolecular complex, along granzymes.  This 
macromolecular complex results in the target cell lysis.  (Fig. 2) 
Eleven granzymes (Grz A-H, M and N) have been described 
(Smyth et al 1996).  Ten of these are expressed in mice and five in humans 
(A,B,H,K and M) (Smyth and Trapani 1995, Trapani et al 2000).  Among 
these, the granzyme B is an caspase because cleaved the substrates after 
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aspartic acid residues and so triggering apoptotic cell death either directly, or 
indirectly via the activation of cellular caspases (for example caspase 3). 
Therefore, the caspases plays a critical role in the mechanism of 
apoptosis.  They are members of a large family of proteases whose members 
have distinct roles in inflammation and apoptosis.  In apoptosis, the caspases 
function in both cell disassembly (effector) and in initiating this disassembly 
in responce to proapoptotic signals (initiator)  Thirteen caspases have been 
identified in the mammalian cells, the effector caspases 3, 6,7 and the 
initiator caspases 1, 2, 4, 5, 8, 9, 10, 14. (Figure 3).  They share similarities in 
amino acid sequence, structure and substrate specificity.  Caspases are among 
the most specific of proteases, with an unusual and absolute requirement for 
cleavage after aspartic acid.  Recognition of at last four amino acids NH-
terminal to the cleavage site is also a necessary requirement for efficient 
catalysis.  The preferred tetrapeptide recognition motif differ significantly 
among caspases and explain the diversity of their biological function 
(Thornberry et al 1998). 
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Fig. 2. Evolving models of CTL/NK-secretory pathway. 
A The initial model, which was developed in the early 1980s when 
perforin was first purified, emphasized the role of perforin as lytic molecule. 
The target cell died because of loss of plasma membrane homeostasis, with 
excessive uptake of water and loss of intracellular contents.  B With the 
realization that granzymes are involved in the inducing cell death cooperatively 
with perforin,and that many cells die by apoptosis, the lytic model was adapted 
to accommodate the passive diffusion of granzymes into the target cell cytosol, 
where they could access key substrate (caspase), leading to death.  C The next 
main findings to be accommodated in the model during the mid to late 1990s 
were that: granzymes enter target cells by endocytosis 
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1.4 The role of the caspase 8 in the apoptosis and in the cellular 
activation 
 Recently, a new clinical phenotype was found, where T, B and NK 
immunodeficit has been observed together with an ALPS-like phenotype.  An 
important study shows the existence of pleiotropic defects in lymphocyte 
activation caused by caspase 8 mutations.  Chun et al. bring that caspase 8, well 
known for its killer effect, plays also an important role in the lymphocytes 
proliferation.  The authors in their study have described a group of patients with 
a severe functional deficit of caspase 8.  In particular, they have shown that 
mutations in homozygosis in caspase 8 gene can produce a condition of multiple 
autoimmunity and immunodeficit.  Clinical examinations showed that subjects 
carriers of this mutation in homozygosis exhibited splenomegaly, 
lymphadenopaty as sign of the involvement of the reticular-endothelial system, 
reduced Fas-induced apoptosis, recurrent respiratory infections, low levels of 
serum Ig without isotipic switch, Virus Herpes Simplex infections and a 
combined T, B and NK immunodeficit. 
The existence of autoimmunity together with immunodeficit supports the 
hypothesis that the same genes, involved in the control of the immune response 
are also responsible of the activation and cellular proliferation. 
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1.5 Animal models 
 The existence of animal models and the generation of knock out mouse 
with mutations of single gene and analysis of related clinical phenotypes greatly 
contributed to ameliorating our knowledge on the pathogenesis of complex 
syndrome of immunodeficiency.  Mice lpr and gld have mutations in Fas and 
FasL genes, respectively, (Nagata et al., 1995) and these mutations lead to loss of 
function.  These mice have a clinical phenotype characterized by high levels of 
auto-antibodies and considerable accumulation of activated and autoreactive 
lymphocytes in secondary lymphoid tissues with consequent involvement of 
lymphoreticular system (Rieux-Laucat F. et al., 2003).  Consequently, mice show 
autoimmune disorders, splenomegaly and lymphadenomegaly (Rieux-Laucat F. 
et al., 2003).  Alterated homeostasis of T and B cells is also been described as 
motive of prevalent limphoproliferative disorders.  In addition, these mice show 
an increase of TCR α/β +, CD4- and CD8- double negative in peripheral blood, 
due to defective intrathymic maturation. 
 Homozygous targeted disruption of the mouse caspase 8 gene was found 
to be lethal in utero (Varfolomeev et al., 1998).  The most important feature of 
the abnormal phenotype of the casp8-/- mutant was marked hyperaemia in the 
abdominal area, superficial capillaries and other blood vessels.  Disruption of the 
casp8 gene appears to result in a dramatic primary or secondary depletion of the 
haematopoietic precursor pool.  Histological examination in mutant embryos 
reveals a congested accumulation of erythrocytes in liver and in blood vessels 
areas.  Normal embryonic liver tissue, with its characteristic early 
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haematopoietic elements, and early liver cells are visible only in the cortical 
area.  The casp8 null embryos also exhibits impaired heart muscle development, 
in fact the ventricular musculature is thin and in some cases not different from 
early mesenchyme.  In fibroblast strains derived from these embryos, the TNF 
receptors, Fas/Apo1 and DR3 are able to activate the Jun N-terminal kinase and 
to trigger IκBα phosphorylation and degradation.  They failed, however, to 
induce cell death.  These findings indicate that caspase 8 plays a necessary and 
non redundant role in death induction by several receptors of the TNF/NGF 
family and serves a vital role in embryonic development. 
 Because caspase 8 deletion is associated with embryonic lethality in mice 
has been generated a conditional knock-out mouse that have consented to study 
in vivo the nonapoptotic function of caspase 8.  This murine model, generated 
with T cell specific delation of caspase 8 (tcasp8-/- ), showed T cell lymphopenia, 
defective activation-induced T cell proliferation, defective T cell responses to 
viral infection that were associated with defective T cell-death induced by CD95 
(Salmena et al 2003).   
Furthermore a new study on mouse  tcasp8-/- model reported the long-term 
physiological consequences of caspase 8 deficiency. This study showed that 
tcasp8-/- mice develop an age-dependent lethal lymphoproliferative and 
lymphoinfiltrative immune disorder characterized by lymphoadenopathy, 
splenomegaly, and accumulation of T cell infiltrates in the lungs, liver, and 
kidneys.  Peripheral casp8-/- T cells manifest activation marker up-regulation 
and are proliferating in the absence of any infection or stimulation (Salmena et 
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al 2006).  Interestingly, the condition described in tcasp8-/- mice manifests 
features consistent with the disorder described in humans with Caspase-8 
deficiency and support the hypothesis that this immune disorder is different 
from autoimmune lymphoproliferative syndrome (Salmena et al 2006).  These 
findings suggest that tcasp8-/- mice may serve as an animal model to evaluate 
caspase-8–deficient patient prognosis and therapy. 
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1.6 Genetics of Caspase 8. 
The human caspase 8 (CASP 8) gene is localized to chromosome band 
2q33-34 and consists of ten exons spanning ~30Kb (Fig. 3).  The structure of 
the human gene, corresponding to the open reading frame (ORF) portion of the 
mRNA, is encoded by eight exons and the coding sequence beging in exon 3.  
CASP 8 is expressed as proenzyme and contain three domains: an NH2-terminal 
domain contain two DEDs domain, a large subunit (~18 KD) and a small 
subunit (~10 KD) contain two cysteine protease domain.  One of the DEDs is 
encoded by exon 3, whereas the second is encoded by exons 4 and 5 and these 
are involved in the regulation of activation (see below).  The linker region, 
located between the DEDs and cysteine protease domain, is encoded by exons 
6-8.  The cysteine catalitic domain are encoding by exons 9-10.  The activation 
of the caspase 8 involves proteolytic processing between domains, followed by 
association of the large and small subunits to form a heterodimer.  This 
processing, after aspartic acid, can be performed either autocatalytically or in a 
cascade by enzymes with similar specificity.  Actually, nine different isoforms 
of caspase 8, all generated by alternative splicing, have been found.  Analysis of 
human adult tissue demonstrated that caspase 8 mRNA is very little express in 
testis, skeletal muscle, kidney and brain.  The highest level of expression was 
found in pheripheral blood leukocytes, consistent with caspase’s 8 role in the 
death of peripheral T cells (Grenet et al 1999, Thornberry et al 1998).   
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Chapter 2 
Research projects 
 
2.1 Clustering of Distinct Autoimmune Disease and Apoptosis 
Even though distinct autoimmune disorders may be associated in the same 
individual, only rare patients exhibit a clear clustering of different autoimmune 
diseases, which are indicative of a common polyreactive autoimmune process 
(Jonsson et al 1996).  Several studies documented a linkage between defined 
HLA molecules and certain autoimmune disorders, such as rheumatoid arthritis 
(RA) (Brown et al 1998), insulin-dependent diabetes mellitus (IDDM) (Nepom 
et al 1998), and celiac disease (CoD) (Fernandez-Arquero et al 1998).  Whilst 
HLA molecules may contribute to the predisposition to a certain disease, the 
mechanism responsible for clustering in a single individual is still unknown. 
Programmed cell death or apoptosis is a finely regulated biological 
mechanism involved in tissue differentiation and homeostasis (MacDonald HR 
et al 1990, Raff MC 1992).  In immune response, apoptosis exerts a suppressive 
influence by limiting clonal expansion and by participating in intrathymic 
negative selection of the T cell receptor (TCR) repertoire (Blakman M et al 
1990). Interaction between Fas and Fas ligand induced apoptosis in several 
lymphoid cell lines and long-term activated peripheral T cells (Nagata S. 1997) 
by activating a death signaling pathway that involves several cysteine proteases 
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named caspases (Cohen GM et al 1997; Salvesen GS et al 1997) (see section 
1.3). 
An acidic sphingomyelinase-producing ceramide, that induces mithocondrial 
alterations probably mediated by GD3-ganglioside (De Maria R et al 1997) is 
also activated, even though its role in Fas signaling is still uncertain (Hsu SC et 
al 1998; Watts JD et al 1997).  Inherited loss-of-function mutations of the Fas or 
FasL genes were reported in association with the autoimmune 
lymphoproliferative syndrome (ALPS), characterized by haematological 
autoimmunities and non-malignant lymphadenopathy with expansion of TCR 
α/β CD4-CD8- double-negative (DN) T cells (Fisher GN et al 1995; Riex-
Laucat F et al 1995; Drappa J et al 1996; Bettinardi A  et al 1997; Pensati P et al 
1997).  Functional Fas deficiency has also been reported in children with 
clinical findings similar to ALPS, but no DN T cell expansion and Fas 
mutations, indicating that alteration of other molecules in the Fas signalling 
pathway causes an ALPS-like syndrome (Dianzani U. et al 1997).   
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2.1.1 Alteration of T cell survival in children with Clustering of 
Autoimmune Disease phenotype 
In the first phase of this study we evaluated Fas- and ceramide-induced 
cell death on T cells from three children affected by clustering of distinct 
autoimmune diseases (CAD) to assess whether a dysregulation of the T cell 
switching-off system may be implicated in the pathogenesis of intense 
polyreactive autoimmunity.   
 Of the three patients enrolled in this study, two patients were selected 
because affected by insulin-dependent diabetes mellitus (IDDM) associated with 
intense autoimmune disorders affecting other organs.  Patient 1 showed Coeliac 
Disease (CoD), autoimmune thyroid disease and juvenile rheumatoid arthritis 
(JRA) in association with IDDM.  Patient 2 showed IDDM and localized 
sleroderma.  Patient 3 had CoD, vasculitis ,recurrent episodes of fever with 
arthritis and iridociclitis.  All patients displayed serum autoantibodies and 
several features similar to ALPS.  The molecular and cytofluorimetric analysis 
revealed that Patient 1 displayed low Fas expression both at transcript and 
protein level associated with expansion of DN T cells. Her resistance to Fas-
induced cell death and sensitivity to ceramide were in line with a defect directly 
involving Fas, as that described in ALPS type Ia.  However, no causal mutation 
has been identified in Fas cDNA.  One possibility is that causal mutation may be 
located in unscreened gene regions, such as the promoter region, intronic splite 
sites, or generally in genomic DNA. 
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 In patients 2 and 3 no expansion of DN T cells was found and Fas 
expression was normal. In patient 3 both Fas- and ceramide-induced cell death 
was abnormal, while in patient 2 only ceramide failed to induce a proper cell 
death.  In these two patients, a further Fas transcript was found that retains 
intron 5 expected to encode for a truncated protein lacking the transmembrane 
and intracellular regions. The aberrant transcript was also observed in the 
healthy mother and brother of patient 3.  Sequence analysis did not reveal any 
change in cDNA, which could explain the abnormal splicing.  However, we 
have been unable to detect this transcript in 11 normal donors.  Whether the 
expression of this form is implicated in the pathogenesis of the polyreactive 
syndrome remains to be established. 
 Soluble forms of Fas are expected to inhibit Fas but not ceramide-induced 
cell death.  Whereas patient 2 was sensitive to Fas trigger and resistant to 
ceramide, the patient 3 was resistant to both stimuli.  It is conceivable that low 
doses of soluble Fas may not inhibit cell death induced by high doses of anti-Fas 
MoAb in the vitro assay, thus explaining the normal Fas function displayed by 
patient 2.  Thus the production of the putative soluble form of Fas could inhibit 
Fas function in vivo and be a cofactor for development of the polyreactive 
autoimmune disease when associated with other genetic and environmental 
factors.  The current opinion is that Fas triggering activates a caspase cascade 
leading to cell apoptosis.  The generation of ceramide is an alternative pathway 
that seems to boost the caspase pathway (De Maria R et al 1997), even though 
the role played by ceramide in Fas signalling is still debated (Hsu SC et al 1998; 
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Watts JD et al 1997).  Moreover the system is under the control of several 
inhibitors belonging to the bcl-2, FLIP and IAP families (Cronin CC et al 1997). 
 Therefore, in both patients 2 and 3, the overt disease and the decreased 
function of the death pathway triggered by ceramide could be explained by the 
concurrence of other genetic factors hitting the pathway downstream from FAS.  
These factors may hit other systems involved in apoptotic induction, such as 
TNF, trail and granzyme systems, which use apoptotic pathways partially 
overlapping that of Fas (Cronin CC et al 1997; Golstein P 1997). 
 It is noteworthy that our patient 2 was resistant to ceramide, but 
responded normally to Fas triggering, which shows that the Fas pathway can 
also function normally when the ceramide pathway is unfunctional and suggests 
that alteration of T cell switching-off systems that are independent of Fas may 
play a role in autoimmunity.   
The data reported in this work indicate that polyreactive autoimmune 
syndromes may be associated with heterogeneous alteration of the immune 
responce switching-off system. 
These results has been published on the Clinical and Experimental 
Immunology see below for the manuscript. 
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2.1.2 Immunological characterization of patients with Clustering of 
Autoimmune Disease phenotype 
 Along with classic forms of ALPS, recently has been identified a novel 
phenotype ALPS-like in which the autoimmunity is associated to specific 
functional deficit of T, B and Natural Killer (NK) cells (Chun H.J. et al 2002).  
This phenotype is due to a homozygous mutation in the gene that encoded for 
the caspase 8 protein.  Therefore on the base of these evidences we performed 
the second phase of this research project. 
In this work, for the first time, we have performed a molecular and 
immunological characterization of a group of pediatric patient affected by 
clustering of autoimmune disease (CAD) phenotype and a functional defect in 
the Fas-induced cell-death.  In particular aim of this study was to investigate if a 
clear clinical phenotype with multiple autoimmunity may be suggest of a more 
complex phenotype of immunodeficiency and if its pathogenesis may be caused 
to a single gene defect. 
 In the wide coorte of the subjects with CAD phenotype that referred to 
our Department, 22 patients, were enrolled on base of the following criteria: 
presence of at least two distinct autoimmune diseases in the same individual 
associated to the defect in the apoptosis Fas-induced.   
The clinical and laboratory features of the 22 patients showed the 
presence of systemic and/or organ-specific autoimmune disorders (Table 1).  
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GH= Growth Hormone 
*T cell survival after anti Fas antibody stimuli. This values are expressed in % The value > or = 79% is pathologic.  
Table 1. Major clinical and laboratory features of CAD patients 
91 Cytopenia, Splenomegaly 22 
90 Splenomegaly, Lymphoadenopathy 21 
80 Mixed Connectivie Tissue, Type 1 Diabetes Mellitus, Ovary Failure 20 
100 Coeliac Disease, Juvenile Idiophatic Arthritis, Type 1 Diabetes Mellitus 19 
100 Autoimmune Trombocytopenia, Autoimmune Thyroiditis 18 
89 Type 1 Diabetes Mellitus, Coeliac Disease 17 
96 Juvenile Idiophatic Arthritis, Coeliac Disease, Uveitis, Vasculitis, 16 
100 Type 1 Diabetes Mellitus, Autoimmune Thyroiditis 15 
79 Vasculitis, Hypergammaglobulinemia, Splenomegaly  14 
106 Coeliac Disease, Type 1 Diabetes Mellitus, Autoimmune Thyroiditis 13 
82 Enteropathy, Candidiasis 12 
91 Autoimmune Trombocytopenia, Autoimmune Thyroiditis 11 
106 Autoimmune Enteropathy, Deficit of GH 10 
106 Autoimmune Trombocytopenia, Deficit of IgA, Uveitis 9 
90 Cytopenia, Autoimmune Trombocytopenia, Linfoadenopatia 8 
104 Urticaria, Atopic Dermatitis 7 
80 Deficit of IgA, Type 1 Diabetes Mellitus, Vitiligo, Psoriasis 6 
79 Type 1 Diabetes Mellitus, Coeliac Disease, Autoimmune Thyroiditis 5 
88 Hypoparathyroidism, Candidiasis, Addison, Deficit of GH, Skin dystrophy, 
Autoimmune Thyroiditis, Ovary Failure, Pancreatitis  
4 
100 Cytopenia, Autoimmune Trombocytopenia  3 
100 Type 1 Diabetes Mellitus, Autoimmune Thyroiditis, Cytopenia 2 
82 Autoimmune Thyroiditis, Type 1 Diabetes Mellitus 1 
*Fas functional (%) Autoimmune Disease Patient # 
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In this group of the patients was evaluated the functional immunological 
deficiency through the lymphocytes proliferative responce after 
phytoemagglutinin and/or anti-CD3 antibody stimuli.  The resulted showed that 
13/22 patients (59%) were also affected by a defect in T cell activation (Fig.1).  
 
Fig. 1 Proliferative response to the PHA and CD3 in a CAD patients 
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The molecular analysis of caspase 8 gene performed in 12 of these 13 
patients revealed the presence of three polymorphisms of which one localized in 
the exon 9 and the other two localized in the intron region flanking the exon 9 
(Fig.2 and Table 2).  At least one of three polymorphic variant was found in 
10/12 subjects. 
 
 
 
Fig.2 Alterations in exon and intron region of caspase8 gene. 
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Table3. Alterations of caspase8 gene in CAD patients 
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Furthermore for ruled out any alteration in perforin-dependent pathway, 
we evaluated the integrity of this pathway in 8/13 subjects with combined 
defect.  In vitro, the assay of citotossicity revealed that 3 children had a decrease 
of cytolytic activity of the lymphocytes T (CTL) and NK cells respect to the 
control subject (Fig. 3).   
 
 
Fig. 3 Evaluation of cytolytic activity in CAD patients with combined 
defect 
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Nevertheless any causative mutation has been revealed in the gene that 
encode for the perforin protein, which have a crucial role in this way of the 
apoptotic pathway.   
In conclusion, the CAD phenotype may be considered a novel clinical 
entities characterized to the presence in the same individual of a wide spectrum 
of autoimmune diseases.  Even though all the patients, of this study, showed a 
functional defect of Fas-induced cell-death, this alteration be not ascribed to any 
causative mutation in Fas gene.  Furthermore, these data, suggests that a 
lymphocyte activation defect is less uncommon than expected in patients with 
severe autoimmunity associated with defective Fas-induced apoptosis.  The 
heterogeneity of the phenotype may be explained cosiderating that the alteration 
of different molecules shared from the apoptosis and activation cell pathways 
may influence the its expression. 
The caspase 8 gene polymorphisms founded in our patients along does 
not cause the disease but its role in the pathogenesis cannot ruled out.  In fact 
this polymorphisms may to represent a predisposing factor for this complex 
disorder. 
These results has been published on the Journal of the “Incontri Pediatrici 
Normanni” International Congress. See below for the manuscript. 
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2.1.3 Apoptosis in the physiology and in the pathology of immune response 
In the final part of this research project we focus our attention on rule of 
apoptosis in the physiology of the immune response and how alterations in 
molecule involved in the apoptotic process may be caused complex pathology. 
The majority of lymphocytes that in vivo expand and proliferate in response to 
foreign antigens, subsequently, will die to maintain a constant cell number 
(Busiello R. et al 2004).  During the initial expansion phase of an immune 
response, also autoreactive clones are generate. Without homeostatic 
mechanisms controlling cell growth, this autoreactive expansion would have 
fatal consequences on the biological functions of the organism.  At the end of an 
immune response, apoptosis or programmed cell-death play a key role to limit 
cellular proliferation, restoring immunological homeostasis, and in the deletion 
of autoreactive lymphocytes, controlling the self-tolerance (King et al 2004).   
The apoptosis is activated by three different pathways: extrinsic, induced by 
death receptor triggering, intrinsic activated by extracellular stimuli and 
secretory (Rieux-Laucat et al 2003).  All these mechanism involved the 
activation of the specific cysteine proteases called Caspase.  Currently, 13 
caspases have been identified in mice and humans.  The subset of caspases that 
clave selected substrates to produce the changes associated with apoptosis are 
know as effector caspase, which in mammalian are caspase 3, 6 and 7.  In most 
instance, these executioner caspase are activated by the initiator caspases: 
caspase8, 10, 2 and 9.  Other initiator caspase are: caspase 1, 4, 5 and most 
likely caspase 14 (Martinon F et al 2004).  The phylogenetic ralathionship of 
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caspases appears to correlated with their function (Lamkanfi et al 2002).  One 
subfamily of caspases is constitud by caspases that have clear functions in the 
execution of apoptosis and includes the initiator caspase 8, 9 and 10 and the 
effector caspase 3, 6 and 7.  However, some of the “apoptitic” caspases, in 
particular caspase 8, have been recently shown to have additional roles in 
lymphocyte proliferation and differentiation (Chun et al 2002, Salmena et al 
2003).  Human caspase 1, 4, and 5 and mouse caspase 11 and 12 constitute 
another group designated inflammatory caspases.  In fact these caspases can be 
involved in apoptosis but their prime function is the regulation of the 
inflammatory processes (Martinon F et al 2004) (Fig. 4).   
 
 
Fig.4 Phylogenies of Caspases 
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The identification of novel human or murine clinical phenotypes and the 
studies of knock out mice for a specific molecule greatly contributed to 
ameliorating our knowledge of such homeostatic mechanisms.  In particular 
studies of patients affected by complex autoimmune phenotype have 
demonstrated a monogenic origin of same hyperimmune syndrome, such as:  
Autoimmune Lymphoproliferative Syndrome (ALPS) (Canale 1967), 
Autoimmune Polyendocrinopathy Candidiasis-Ectodermal Dystrophy 
(APECED) (Neufeld 1980), Immunodysregulation, Polyendocrinopathy, 
Enteropathy, X linked syndrome (IPEX) (Wildin 2002).  These are caused to 
alterations of molecules involved in cell apoptosis.   
ALPS 
Hematologic autoimmune disorders associated with nonmalignant 
lymphadenopathy are the prominent clinical features of the ALPS, whose 
molecular characterization led to define five distinct entities on the basis of the 
location of the defect in the Fas signaling cascade (Rieux-Laucat et al 2003).  
The ALPS0 represents the human analog of the lpr mice (Fas-/-) and is 
associated to a complete absence of Fas molecule.  The ALPSIa, represents the 
most frequent form of the syndrome and is associated to heterozygous mutation 
of Fas gene.  The ALPSIb is associated to a molecular alteration of the ligand of 
Fas, FasL while the ALPSII is associated to an alteration of the caspase 10 gene.  
Moreover, ALPSIII represents a large group of ALPS patients in which the 
molecular defect still remains to be identified.  Along with typical form of this 
syndromes in several form, ALPS-like the autoimmune process is associated to 
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an immunodeficit which leads to an increase susceptibility to viral infection.  In 
a recent study, a novel form of ALPS  has been identified.  This form is 
characterized by a specific immunodeficit of T, B and NK lymphocytes and is 
associated to an alteration of caspase 8 gene (Chan et al 2002) (Table 4). 
 
Table 4.  Gene mutations in Autoimmune Lymphoproliferative Syndrome. 
Disease Gene 
ALPS 0 CD95/Fas 
ALPS IA CD95/Fas 
ALPS IB CD168/FasL 
ALPS II Caspase 10 
ALPS III unidentified 
ALPS and Immunodeficiency Caspase 8 
 
APECED  
APECED is characterized by the variable occurrence of T cell and B cell 
mediated autoimmune diseases targeting various endocrine glands  (parathyroid, 
thyroid, adrenal glands, gonads, pancreas, liver, skin and erythrocytes).  It is 
often associated with chronic mucocutaneous candidiasis and ectodermal 
dysplasia  (Fisher 2004).  It is inherited as a Mendelian disease with an 
autosomal recessive mode. Loss of function mutations in Autoimmune 
Regulator gene (AIRE) cause the disease (Fisher 2004).  A similar phenotype 
has been noted in Aire-/- mice (Fisher 2004).  Considerable interest was sparked 
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by the fact the AIRE is expressed mainly in medullary thymic epithelial cells 
and that the gene encodes for a protein  with a DNA binding activity and gene 
transactivation capacity (Fisher 2004).  Recently, several reports have 
demonstrated that AIRE actually regulates the ectopic expression in medullary 
thymic epithelial cells of tissue specific proteins normally found in  terminally 
differentiated organs, such as preproinsulin and zona pellucida glycoprotein 3 
(Fisher 2004).  These results strongly indicate that AIRE expression is key in 
central tolerance to a set of self proteins, although the mechanism by which 
AIRE triggers their gene expression is still unknown.  
IPEX 
The IPEX syndrome is a multisystemic autoimmune disease with an early onset 
and often fatal outcome (Fisher 2004).  Severe enteropathy with diffuse and 
massive T cell infiltration and mucosal destruction variably associated with 
diabetes, eczema and autoimmunity toward blood cells are hallmarks of this 
disease.  Loss of function mutations in the gene Foxp3 are causal (Fisher 2004).  
Foxp3 encodes a DNA binding  protein of the forkhead family with a winged 
helix domain.  It is expressed mainly by a subset of regulatory CD4 T cells that 
also express CD25 (Fisher 2004).  There is a similar natural mutant in mice : the 
scurfy mice (Fisher 2004).  As Foxp3 is essential for regulatory T cell induction, 
this phenotype seems to be the consequence of a deficiency in regulatory T 
cells.  The dominance of normal over mutated cells in obligate carriers and after 
bone marrow transplantation, respectively, results in a mixed chimerism (Fisher 
2004).  The IPEX phenotype differs from APECED and these differences 
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demonstrate the non redundancy of the mechanism controlling autoimmune 
disease.  This review has been published on the Journal of Prospettive in 
Pediatria. See below for the manuscript 
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2.2 Peripheral GH insensitivity is a distinct disorder in Idiophatic Short 
Stature 
Short stature is the most important clinical problem considerated the high 
frequency in childhood.  In many case the short stature may be the sign of a 
wide variety of pathologic condition or inherited disorder.  Indeed, decreased 
childhood growth resulting in short stature is caused by endocrine or 
chromosomal abnormalities, genetic defects in endochondral bone formation, 
malnutrition, chronic systemic disease, or psychosocial deprivation.  In spite of 
that, in many children a specific etiology for the growth failure cannot be 
identified and this condition is referred to as Idiophatic Short Stature (ISS).  The 
criteria used for to define this pathology are 1) a height of more than two 
standard deviation below the mean; (2) normal or slow height velocity; (3) 
normal birth weight; (4) absence of specific endocrine abnormalities (including 
GH deficiency) and no evidence of chronic physical or psychological illness [1-
3 in Blair 2002] and idiophatic short stature  is cosiderated a diagnoses of 
exclusion.   
Actually, the teraphy of the children with ISS consist in the administered 
to exogenous recombinant human GH (rhGH) (Manmohan A 2005). 
Before 1980, GH was administered exclusively to GH deficient (GHD) 
children who were unresponsive to stimulation tests. Subsequently, many 
investigators studied the effects of GH in very short children who were GH 
sufficient and were growing at a subnormal velocity for their age.  Left 
untreated, many of these short children have failed to reach their midparental 
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target heights, consequently, opinions differ as to its impact on final heights 
(Buchlis JG et al 1998).   
In these cases, the short stature may be caused to the defect in 
spontaneous GH secretion associated with the normal response to GH 
stimulation test (Spiliotis BE et al 1984) or to GH inactivity (Kowarski AAet al 
1978).  Nevertheless, the first mechanism has been found in a rare cases 
(Kerrigan JR et al 1993) while the second mechanism, also recently, has been 
reported (Takahashi Y et al 1997).  Furthermore, it has been recognized that 
some children with ISS may have peripheral insensitivity to GH (GHI) at 
different extents of severity (Goddard Ad et al 1995).  Overall, studieds in the 
last years have elucidated that receptor defects or molecolar alterations of 
downstreem elements in the signaling cascade may lead to a considerable 
number of diseases characterized by total or partial unresponsiveness of the 
target organ to appropiate stimuli (Rosenfeld RG 1994). 
Laron syndrome (LS) represent the classical prototype of GH 
insensitivity.  This is a rare autosomal recessive disorder characterized by severe 
peripheral resistence to the physiological action of GH (Rosenfeld RG et al 
1994).  Although diagnostic criteria to define patients with severe GHI are well 
astablished (Woods KA et al 1996), the identification of patients with milder 
forms is still debated (Johnston LB et al 1999).   
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2.2.1 Peripheral GH insensitivity: a post-receptorial defect 
Considered that for understanding regulation of normal growth and 
metabolism, it is essential to understand the molecular basis of growth hormone 
(GH) action, in this first phase of research we describe the physiopathological 
role of GH hormone in peripheral GH insensitivity disorder.  Furthermore we 
provide to delineate possible diagnostic algorithms to help the paediatrician 
promptly recognize in a heterogeneous group of ISS that forms of short stature 
due to a receptorial or post-receptorial defect. 
The GH hormone play an important role in the cellular growth, 
differentiation and metabolism but its diverse effects are elicited by binding of 
GH to its receptor (GHR).   
The human growth hormone receptor (GHR) belongs to the GH-PRL-
cytokine receptor superfamily and consists of three domains: an extracellular 
domain responsible for hormone binding and receptor dimerization, a 
transmembrane domain, and an intracellular domain that initiates intracellular 
signaling (Postel-Vinay MC et al 1995).  A soluble form of the GHR called high 
affinity GH binding protein (GHBP) is present in the circulation of normal 
individuals end acts as a reservoir and buffer for circulating GH.  It is produced 
as a result of proteolytic cleavage of the extracellular domain from the rest of 
the receptor protein.  GH has been shown to bind sequentially to two GHBPs, 
leading to the hypothesis that GH binding causes both dimerization of GHR and 
conformational changes important for GH function.  These changes result in 
increased binding to GHR of JAK2, a nonreceptor tyrosine kinase, and promote 
 72 
activation of JAK2.  In turn, both GHR and JAK2 are phosphorylated on 
tyrosines by the activated JAK2.  These phosphorylated tyrosines serve as 
docking sites for SH2 domain-containing signaling molecules.  Subsequent 
signaling events include activation of MAP kinases, via a 
SHC+Grb2+Sos+ras+raf+MAPK pathway.  MAP kinase substrates include 
other protein kinases as so as transcription factors that are phosphorylated in 
response to GH and are responsible for several actions of GH.  A recently 
described family of transcription factors that serve as signal transducers and 
activators of transcription (Stat) participates in GH signaling between the 
receptor and the nucleus.  Stat proteins are latent cytoplasmic factors containing 
SH2 and SH3 domains.  Upon tyrosyl phosphorylation, often via a JAK kinase-
initiated cascade, cytoplasmic Stat proteins complex with other Stat and/or non-
Stat proteins, translocate to the nucleus, bind to DNA, and activate transcription 
of target genes (Carter-Su C. et al. 1996).   
The effects of GH on growth are mostly mediated by intermediate factors, 
of which the insulin-like growth factor-I (IGF-I) is the most studied.  The linear 
growth is a complex process and GH and IGF-I participate as combined factors 
or separately to this process.  Thus, GH appears to have many cellular effects 
that are independent of IGF-I, and are most probably direct effects of GH 
mediated by its cognate receptor (Le Roith Trends in Endocrinol 2001). 
Recently, has been reported that the GHR stimulation actives several 
pathways.  The coordinate action of the proteins involved in this pathway leads 
to the expression of the appropriate GH functions (Winston LA 1995).  
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Therefore, any proteins alteration and/or protein phosphorylation events 
alteration in the transduction mechanism may be cause to a peripheral GH 
insensitivity. 
Moreover studies of pathogenesis in patient with GHI showed that in 
same cases this condition is associated to molecular alteration of GH-R gene.  In 
classis Laron syndrome nearly 40 distinct mutations and /or exon deletions have 
been identified (Rosenbloom AL et al 1999).  On the contrary, molecular 
analysis performed in children with a milder form of GHI reveals that only in 
few cases this disorder is associated to mutations in GH-R gene (Goddard AD et 
al 1997, Sanchez JE et al 1998).  Take together, this data suggest that other 
molecules involved in GH-R signaling might be altered and to cause a partial 
responsiveness to GH hormone stimulation. 
Thus far the GH stimulation test is a useful tool to help to identify the 
patient without GH deficiency.  This test is performed administrated exogenous 
GH for 4 consecutively days.  A increase of the serum levels of IGFI I (main 
mediator of GH function) more than 20% of the basal value is considerate a 
positive test response (Blum WF 1994).  This evaluation allow to leave out a 
structural or functional defect of the GH-receptor.  Conversely, no increase of 
the serum levels of IGFI indicate no responsiveness of the peripheral organ to 
the GH and this associated to normal or elevated serum levels of  GHBP suggest 
a defect in signaling transduction mechanism of the GH-R. 
This work has been published on Italian Journal Pediatrics see below for 
the manuscript. 
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2.2.2 Abnormal GH Receptor Signaling as a marker for Peripheral GH 
insensitivity  
As GHI encompasses a wide spectrum of clinical phenotypes, ranging 
from classical complete forms and partial deficiencies, the identification of these 
patients is often difficult, and the prevalence of such cases may be 
underestimated (Saenger P 1999).  Aim of  this research were ascertain whether  
integrating functional provocative assays, analysis of receptor induced 
biochemical alterations and molecular studies may help unravel the complexity 
of ISS and lead to identification of more reliable markers of GHI.   
The results obtained in this study revealed reduced tyrosine 
phosphorylation in two of 14 ISS children following GH stimulation of 
peripheral lymphocytes, associated with low basal and GH-stimulated serum 
IGF-I.  In the patient 3 no tyrosine phosphorylation was observed while in the 
patient 12 the biochemical alteration was selective, in that it concerned 
exclusively the protein migrating in the 119 kDa area, whose size corresponds to 
that of Jak2, but immunoprecipitation experiments showed a normal JAK 2 
phosphrylation thus suggesting that a different molecule migrating in the same 
area of JAK 2 and yet be defined was involved in the process .  The molecular 
analysis of GHR in these patients revealed two heterozygous polymorphism: 
G168A in the exon 6 and I526L in the exon 10 in the patient 3 and an 
homozygous polymorphism I526L in the exon 10 in the patient 12.  Only one 
heterozygous mutation Arg 161 Cys was found in patient 5 that showed a normal 
incremental response to GH.  Thus, a possible mechanism to explain the wide 
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phenotypic variability of heterozygous mutation of GHR is that there are other 
genes that may interact with the signaling pathway, thus modifying the clinical 
phenotype.  This work has been published on Clinical Endocrinology and 
Metabolism, see below for the manuscript.   
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2.3 Human Severe Combined Immunodeficiency (SCID) phenotype
 Severe Combined Immunodeficiencies (SCID) encompasses a wide 
spectrum of disorders of both cell-mediated and humoral immunity.  Defects in 
lymphoid differentiation may lead to the complete absence of T and B cells (T-
B- phenotype) or, alternatively, may predominantly affect T lymphocyte 
development (T-B+ phenotype) (Fischer A. 1997).  These form are in 
generally fatal within the first years of life, although a few typical cases may be 
characterized by a milder phenotype.  Thus far, all the different forms with a 
known molecular basis are caused by mutations in genes that encode for 
proteins selectively expressed in the hematopoietic tissue, which lead to intrinsic 
abnormalities of lymphocyte function.  This implies that in most patients, the 
affected cell line can be replaced by stem cells from healthy donors.  However, 
an appropriate, productive immune response also requires appropriate 
intercellular connections. A relation between the hematopoietic precursor and 
the thymic epithelial component plays a crucial role in cell ontogeny and in 
negative and positive selection (Anderson G. 1994).   
Our group in 1999 reported on 2 sisters affected by a novel form of SCID 
(MIM 601705) characterized by T cell defect associated with congenital 
alopecia and nail distrophy.  This complex phenotype represents the human 
homologue of mouse Nude/SCID phenotype (Pignata et al 1996).  
Subsequently, the sisters were found to carry a nonsense the R255X mutation in 
the homozygous status in the highly conserved winged-helix-nude (WHN) gene 
(Frank J et al 1999).  Alteration of this gene is responsable for mouse Nude 
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/SCID (Nels et al 1994, Segre et al 1995).  WHN is a forkhead-winged helix 
transcription factor whose expression is restricted to the thymic epithelium, 
epidermis, and hair follicle (Lai et al 1993, Kaufmann et al 1996).  Human 
Nude/SCID is the first example of a human SCID caused by a gene not 
expressed in th hematopoietic cells.  Before this molecular alteration was 
identified, the younger of the 2 WHN-/- sisters underwent allogenic bone 
marrow transplantation (BMT) because of her critical clinical and immunologic 
condition.   
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2.3.1 Immunologic reconstitution after bone marrow transplantation  
in human Nude/SCID phenotype   
 The current study was undertaken to evaluate the role of the thymus in 
immunologic reconstitution and long-term efficacy of bone marrow 
transplantation (BMT) in the younger of the 2 sister affected by human 
Nude/SCID phenotype. This is a unique model with which to investigate the 
role of intrathymic connections, between thymic epithelia and hematopoietic 
progenitors, in the regeneration and maintenance of T-cell responces after 
allogenic BMT. 
 The children was born of consanguineous parents.  The clinical 
feather showed a complete absence of hair, distrophic nail, absence of thymus 
and severe functional T-cell immunodeficiency.  At the age of 5 months the 
patient underwent HLA-identical total bone marrow transplantation from her 
unaffected brother.  The immunophenotype performed at regular interval during 
post-BMT follow-up revealed that despite an increases in CD3+,CD4+,and 
CD8+ cells, CD4+CD45RA naive lymphocytes were not generated.  
Conversely, naive CD8+ cells were normal.  The proliferative responses of 
peripheral lymphocytes to CD3 cross-linking showed an initial improvement 
that progressively declined 48 months after BMT.  Furthermore, the 
proliferative responses to common mitogens of lymphocyte obtained from the 
WHN -/- patient revealed a remarkable deficiency compared with the 
genotypically identical donor cells grown in the WHN +/- environment.  
Analysis of T-cell receptor (TCR) repertoire of CD4+ cells revealed that only 3 
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of 18 Vβ families had an alterated CDR3 heterogeneity length profile.  
Conversely, CD8+ lymphocytes showed an abnormal distribution in most Vβ 
families. These data indicate that the thymus is differentially required  in the 
reconstitution of CD4+ and CD8+ naive subsets and in the maintenance of their 
repertoire complexity.  Despite the favorable clinical course after BMT, our data 
suggest that this terapeutic procedure is ineffective in the long term cure of this 
form of SCID.  These results has been published on Blood see below for the 
manuscript. 
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2.3.2 Molecular screening for the Nude/SCID gene alteration in isolated 
population 
Since the first 2 sisters investigated, carrying the R255X mutation in the 
homozygous state, born to consanguineous parents originating from small 
community in southern Italy (Pignata et al 1996), other cases were found in 
same community.  So in this phase of research, the genetic screening for the 
presence of the FOXN1 R255X mutation was performed in an attempt to 
identify an ancestral founder effect.  In fact due to the geographical location of 
the village, lying in the mountains between Naples and Salerno, and the elevated 
rate of endogamy, the population may be considered isolated.  Moreover, we 
have genotyped 2 microsatellite markers, D17S2187 and D17S1880 flanking the 
FOXN1 gene on chromosome 17 to define whether a founder chromosome is 
shared by individuals carrying the R255X mutation.  Molecular analysis 
revealed that 55 subjects, corresponding to 6.52% of the population were found 
heterozygous carriers of the mutation.  In these 55 subjects, originated from 39 
families, we perform a genealogical study.  Through the archival database, 
common ancestors were identified for the 55 heterozygous carriers.  They are 
linked in an extended 7 generational pedigree comprising 483 (Figure 1) 
individuals founded by a single ancestral couple born in 19th century.  This 
work has been very important also to give a prenatal diagnosis support to this 
population.  These results has been published on the Annals of Human Genetics 
see below for the manuscript. 
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2.4 A crosstalk between Immune System and Endocrine System  
The crosstalk between Nervous System (NS), Endocrine System (ES) and 
Immune System (IS) has been documented.  Recently, a large number of 
experimental evidences show a tight interaction between IS and ES.  In 
particular, the growth hormone as GH and IGF-I which play a key role in the 
growth and in the tissue metabolism seems to play a key role in the maintenance 
and in homeostasis of IS.  However the mechanism of action and the role of 
production by leucocytes of hormones with an endocrine function still to be 
clarified.   The aim of this phase of this research project is to clarify the 
biochemical and molecular mechanism of the of the network of ES and IS and 
to clarify if an alteration of this complex network may be implicated in the 
pathogenesis of Congenital Immunodeficiency (CID).  Severe combined 
immunodeficiencies (SCIDs) represent a wide spectrum of illnesses, which 
differ in either the qualitative or quantitative alterations of T-, B- and natural 
killer- (NK-) cell (Fischer et al  1997).  Most forms of SCID are associated with 
molecular alterations of genes selectively expressed in hematopoietic cells and 
implicated in cell differentiation/activation process.  Thus, classical symptoms 
are generally considered those related to the immunological impairment that 
results in increased susceptibility to infections.  Since patients usually die by the 
first year of age without an effective treatment, the clinical phenotype is 
predominated by the life-threatening problems. 
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2.4.1 X-SCID phenotype associated with growth hormone 
hyporesponsiveness 
X-linked Severe Combined Immunodeficiency (X-SCID) is the most 
common form of the disease accounting for approximately half of all cases 
(Noguchi et al 1993; Leonard et al 2001).  The gene responsible for X-SCID is 
IL2RG that encodes for the common cytokine receptor γ chain (γc), a member of 
the cytokine receptor class 1 superfamily.  The molecule represents a shared 
component of several receptors critical for the development and function of 
lymphocytes (Leonard et al 2001).   
In this phase of research we described a patient affected with a X-linked 
SCID who received a BMT late at 5.2 years of age and therefore his short 
stature became evident.  This patient showed a immunodeficiency due to a T-
cell activation defect associated with peripheral GH insensitivity and abnormal 
haematopoiesis.  The pathogenic mechanism underlying this complex phenotype 
involves signal transduction through both TCR and GHR.  These receptors, as 
many other receptors, trasduce signals through a cascade of biochemical events 
involving phosphorylation/dephosphorylation processes (Klausener et al 1991).  
Even though a few signaling molecules are tissue specific, most of the signaling 
pathway are not restrict to a certain cell type.  In this study we focuses our 
attention on the JAK2/STAT5 molecules involved in signaling trough several 
cytokine receptor even included GHR (Argetsinger et al 1996, Winston et al 
1995).  In this patient, the analysis of signal transduction revealed a defective 
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pattern of protein tyrosine phosporilation after TCR and GHR engagement.  In 
particular, CD3 X-L failed to increase phosphorilation of protein of 42-44, 56-
60,70 and 85 kD usually phosphorilated upon this activation (Del Giudice et al 
2000).  Similarly, after the GH stimulation there was no increase in the signal 
regarding the 2 protein of 105 and 119 kD generally phosphorilated upon GH 
stimulation, corresponding to JAK2 and STAT5 molecules.   
Experimental evidence and knock out mice indicate that alteration of 
STAT5A and 5B result in an impaired response to a number of cytokines, 
including GM-CSF, IL-2, IL-3, IL-5, GH and erythropoietin (Teglund et al 
1998, Socolovsky et al 1999).  In particular, activation of STAT5B is considered 
a prominent event in GH signaling and is crucial for the regulation of 
transcription of GH-responsive genes, including the gene encoding for insulin-
like growth factor-I (IGF-I), which mediates many of the GH biological 
functions (Clark et al  1997; Dorshkind et al 2000; Le Roith et al 2001).  
However, in this study, mutational screening and expressional analysis failed to 
reveal any molecular alteration of GHR, JAK2 and STAT5A/B genes in the 
patient with X-SCID and peripheral GH hyporesponsiveness.   
Even though, to our knowledge, an extrahematopoietic role of γc has not 
yet been demonstrated, although the abundance of the protein in non-
hematopoietic cells would imply additional functions for this element (Du et al  
2005; Ozawa et al  2004), our data suggest the hypotesis that in this patient the γ 
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chain defect is the common underlying pathogenic mechanism for both 
endocrinological and immunological problems.   
These results has been published on the Clinical and Experimental Immunology, 
see below for the manuscript. 
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2.4.2 Functional Interaction of Common Gamma Chain and Growth 
Hormone Receptor Signaling Apparatus  
Since, in the previously research has been hypothesized a role for the γc 
chain in GHR signaling, aim of this study has been evaluated, for the first time, 
the functional interaction between GHR and the common γ element in either 
freshly isolated or Epstein-Barr virus (EBV) transformed lymphocytes from X-
SCID patients and healthy subjects.  In particular, the functional response to GH 
stimulation, the pattern of GHR induced protein tyrosine phosphorylation and 
GH induced translocation from the cytoplasm to the nucleus of STAT5 were 
evaluated.   
The results showed that the proliferative response to GH stimulation of 
the B cell lines of γc-negative patients was impaired despite a comparable 
cellular expression of GHR molecules to controls.  The functional interaction 
between γc and GHR leads to the activation and intranuclear translocation of 
STAT5b protein.  The results showed that in patients, after GH stimulation, no 
phasphorylation of STAT5 was observed.  In addition, the molecule localization 
through confocal microscopy revealed that in B cell lines of patients no nuclear 
traslocation of STAT5b following GH stimulation occurred differently from 
controls.  Biochemical analysis of the nuclear extracts of γc-negative cell lines 
provided further evidence that the amount of STAT5b and its phosphorylated 
form did not increase following GH stimulation.  In patients, cells reconstituted 
with wilde type γc abnormal biochemical and functional events were restored 
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resulting in nuclear traslocation of STAT5.  Finally, confocal experiments 
revealed that GHR and γc were colocalized on the cell membrane. 
Our study demonstrates the existence of a previously unappreciated 
relationship between individually well studied elements, such as GHR and γc, 
and signaling pathways. 
Crosstalk between receptor signaling systems is now emerging as an 
important and exciting area of signaling research.  These results has been 
published on Journal of  Immunology, see belw for the manuscript.  
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2.5 Brain Migration Disorder and Immune System 
Neuronal migration disorders may cause mental retardation and epilepsy. 
Actually, several brain migration disorders are known and the lissencephaly is 
one of these.  Classic lissencephaly (type I) is a brain malformation caused by 
abnormal neuronal migration at 9 to 13 weeks' gestation, resulting in a spectrum 
of agyria, mixed agyria/pachygyria, and pachygyria. It is characterized by an 
abnormally thick and poorly organized cortex with 4 primitive layers, diffuse 
neuronal heterotopia, enlarged and dysmorphic ventricles, and often hypoplasia 
of the corpus callosum (MIM 607432).  The genetic basis of agyria-pachygyria-
band spectrum is beginning to be elucidated and mutation in the lissencephaly  
gene (LIS1) or doublecortin gene (DCX also Known as XLIS) have been 
reported (Pilz DT et al 1998). 
Nevertheless, the pathogenetic mechanism underlain these disorders still 
remains to be thoroughly defined.  
In the immune system T-cell activation is a complex biochemical process 
that involves many signaling molecules, such as tyrosine kinases and 
phosphatases, which in turn active other proteins through phosphorylation/ 
dephosphorylation events (Perlmutter RM 1993).  Predominant T-cell 
immunodeficiencies encompass a wide number of distinct entities whose 
pathogenetic mechanism are coming to be extensively defined (Arnaiz-Villena 
A et al 1992; Stiehm ER 1993).  However, the mechanism of most functional T-
cell activation deficiencies still remains to be elucidated.   
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The nervous and immune systems share several molecules that are not 
tissue-specific, therefore, their alteration should result in a multisystem disorder.  
Even though recurrent infections in children with brain migration 
disorders are frequent, no extensive examination of the immune system has been 
performed in these patients (Dobyns WB, 1987). 
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2.5.1 Combined defect of neuronal migration and hyperactivity of Fyn 
Tyrosine Kinase 
In this research, for the first time, we study the function of T- cells 
immune system in a patient affected by a brain migration disorder and recurrent 
infections.  
The preliminar genetic analysis was performed and no genetic cause for 
the neuronal migration disorder was found. 
The immunological evaluated revealed that the proliferative response to 
the common mitogenic stimulation was lower than that observed in age-matched 
controls.  The PHA stimulation failed to induce a proper up-regulation of 
membrane expression of T-cell activation markers.  Moreover this patient failed 
to produce specific antibodies.  We also documented in lymphocytes 
abnormalities in the signal transduction process that follows triggering of the T-
cell receptor/CD3 complex.  The stimulation of the complex failed to induce 
protein tyrosine phosphorylation (Fig. 2a).  A high constitutive 
autophosphorylation activity of the 59kDa Fyn tyrosine kinase was also found 
(Fig. 2b).  This kinase participates in the T-cell activation process.  In particular, 
it has been documented that in experimental anergy TCR stimulation leads to 
the activation of Fyn, differing from the productive immune response which 
requires the recruitment to the receptor of the different array of molecules, but 
no Fyn (Byrd SE et al 1989).  In a similar way, the mechanism of the T-cell 
defect in our patient seems to involve this kinase.   
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This work would suggest that abnormalities in Fyn signaling may be an 
underlying mechanism for a combined defect of neuronal migration in agyria-
pachygyria band spectrum and of T-cell functionality.  These results has been 
published on the Neuropediatrics see below for the manuscript. 
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Chapter 3 
Technologies  
 
3.1 Evaluation of Fas-induced cell death 
 Fas-induced cell death was evaluated as previously reported on activated 
T-cell lines obtained by treating peripheral blood mononuclear cells (PBMC) 
with phytohemagglutinin (PHA) at days 0 (1 µg/mL) and 12 (0.1 µg/mL). Cells 
were then cultured in RPMI 1640 + 10% FCS + recombinant IL-2 (2 U/mL) 
(Biogen, Geneva, Switzerland).  Fas function was assessed 6 days after the 
second stimulation (day-18 T cells), by incubating with control medium or 1 
µg/mL anti-Fas mAb (CH11, IgM isotype, UBI, Lake Placid, NY) in the 
presence of 1 U/mL recombinant interleukin 2 (rIL-2) and 5% FCS to minimize 
spontaneous cell death.  Cell survival was evaluated after 18 hours by counting 
alive cells in each well by the trypan blue exclusion test.  Assays were 
performed in triplicate and analysed by a blind observer.  Cells from 2 normal 
donors were included in each experiment as a positive control.  Results were 
expressed as relative cell survival percentage, calculated as follows: (total live 
cell count in the assay wells/total live cell count in the untreated samples) x 100.  
Spontaneous cell loss in the control well was always less than 10% of the 
seeded cells and similar in cultures from the patients and normal donors.  Cell 
death was evaluated both indirectly, by counting total surviving cells by the 
trypan blue exclusion test, or directly, by cytometric determination of the 
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proportion displaying DNA fragmentation after staining with propidium iodide 
or those stained by annexin to confirm Fas resistance. Fas function was defined 
defective when cell survival was higher than 78 %, which was the 95th 
percentile of the response displayed by normal controls. 
 
3.2 Molecular analysis of the Fas and caspase-8 genes 
 Mutation analysis of the Fas (TNFRSF6) and caspase-8 genes were 
performed by DNA genomic sequencing. DNA was extracted from PBMC with 
standard methods. Eight fragments spanning the 5’UTR and the 9 exons of the 
Fas gene were amplified in 20 µl final volume containing 12 pmol of each 
primer, 50 ng of genomic DNA and 0,5 units of AmpliTaq (Applied 
Biosystems, Warrington, UK).  PCR conditions for caspase-8 gene 
amplification were as follows: sixteen fragments spanning the 10 exons and 
intron-exon boundaries were amplified in 50 µl final volume containing 25 
pmol of each primer, 100 ng of genomic DNA, 0.2 mM dNTPs and 1.25 units of 
AmpliTaq Gold (Applied Biosystems) in the buffer provided by the 
manufacturer.  Amplification was performed in a Gene Amp PCR System 9700 
(PE Applied Biosystems).  The PCR products were sequenced using a Big Dye 
Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) and an ABI 
PRISM 3100 Genetic Analyzer (Applied Biosystems). 
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3.3 Cells and cell cultures 
Mononuclear cells (PBMC) were obtained from patients and normal 
donors heparinized peripheral blood by Ficoll-Hypaque (Biochrom) density 
gradient centrifugation.  Upon informed consent, lymphoblastoid cell lines 
(BCLs) were generated by Epstein-Barr virus immortalization of patients and 
controls PBMC using standard procedures.  Cells were maintained in RPMI 
1640 (Biochrom) supplemented with 10% fetal bovine serum (Gibco), 2 
mmol/L L-glutamine (Gibco), and 50 µg/ml gentamycine (Gibco), and cultured 
at 37°C, 5% CO2.   
 
3.4 Proliferative assay 
BCLs or PBMC (1 X 105 cell/200 µl well) were cultured triplicate in 96-
well U-bottomed microtiter plates (Falcon®, Becton Dickinson) with or without 
appropiate stimuli for 4 days.  The proliferative response was evaluated by 
thymidine uptake from cultured cells pulsed with 0.5 µCi [3H]thymidine 
(Amersham International) 8 h before harvesting . 
 
3.5 Flow cytometry 
The expression of specific protein was detected using specific antibodies 
(Santa Cruz) by indirect immunofluorescence using a second-step incubation 
with a FITC-conjugated secondary antibodies (Pierce).  After washing in PBS, 
cells were incubated for 20 min with the specific antibodies and 30 min with 
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secondary antibodies.  After staining, all samples were washed in PBS and 
acquired on the FACScan flow cytometer (Becton-Dickinson) using Lysis I 
software. 
 
3.6 Natural Killer function 
Infected target cells (K562) were pulsed for 1 h at 37 °C with 
Cr51(Amersham Pharmacia, Buckinghamshire, England) (30 µCi/106 cells) and 
washed three times with culture medium before the addition of effector cells.  
Specific lysis was measured in a triplicate assay performed with 5x103 target 
cells mixed with different ratios of effector cells (E:T= 25:1 to 3.125:1) in a 
total volume of 200 µl.  After a 5 h incubation at 37 °C, 100 µl culture 
supernatant were collected and the amount of Cr51 release was counted.  The 
percentage of specific lysis was calculated as follows: 100 x (specific release-
spontaneous release)/(total release-spontaneous release). 
 
3.7 Cell stimulation and protein extraction 
Prior to appropiate stimuli treatment, the cells were made quiescent 
through incubation in RPMI 1640 minus serum for 8-12 h.  The stimuli was 
used at 37°C at the reported concentration in RPMI 1640 for the reported time.  
Incubations were terminated by washing cells with ice cold phosphate-buffer 
saline (PBS; BioWhittaker) followed by solubilization in 100 µl of lysis solution 
containing 20 mM Tris (pH 8), 137 mM NaCl, 1% Nonidet P-40, 10 mmol 
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EDTA, 1 mM phenylmethylsulfonylfluoride, 1 mM sodium orthovanadatum 
(Na3VO4), 5 µg/ml leupeptin and 5 µg/ml aprotinin.  The cell lysates were 
stored at -80°C for Western blot analysis.  Nuclear extracts were prepared by the 
standard method and were subsequently mixed with sample buffer. 
 
3.8 Western blot 
Immunoblotting using phosphotyrosine monoclonal antibody was 
performed as previously reported.  Immunoblotting using specific antibody was 
performed according to the vendors protocols.  In brief, protein samples 
separated by SDS-PAGE were transferred onto Mixed Cellulose Esters 
membranes (Immobilon-NC Mixed Cellulose Esters 0.45µm; Millipore).  The 
membrane was incubated at room temperature for 1 h in blocking buffer 
consisting of 10% Bovin Serum Albumin (BSA) in wash buffer (10 mM Tris, 
pH 7.5, 100 mM NaCl, 0.1% Tween 20).  The membrane was then washed three 
times in wash buffer and incubated 1 h at room temperature or overnight at 4°C 
with the specific antibody.  The membrane was then washed three times and an 
appropriate IgG horseradish peroxidase-coniugated secondary antibody was 
used for the second incubation.  After further washings, the membrane was 
developed with ECL developing reagents, and exposed to X-ray films according 
to the manufacturer’s instructions (Amersham Biosciences).   
 
3.9 Confocal microscopy 
After appropriate stimulation, quiescent cells were rinsed in ice-cold PBS 
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and fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.0) for 30 
min at room temperature.  After four rinses of 5 min in PBS, the cells were 
centrifuged in a Shandon Cytospin III (Histotronix) onto a glass slide and 
permeabilized by incubation in a 0.2% Triton X-100 solution for 20 min.  The 
cells were then incubated for 1 h at room temperature with specific antibody 
diluted in PBS containing 1% BSA.  After four washings for 5 min in PBS, the 
cells were incubated for 1 h at room temperature with FITC-conjugated 
secondary antibody.  After washing in PBS, the glass slides were mounted under 
a coverslip in a 50% glycerol/50% PBS solution.  The slides were analyzed by 
laser scanning confocal microscopy, using a Zeiss LSM 510 version 2.8 SP1 
Confocal System. 
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Chapter 4 
4.1 Summary 
 
Primary immunodeficiency diseases (PIDs) represent a group of most 
heterogeneous syndromes characterized by development or functional defect of 
the Immune System.  Thus far, more than 200 distinct well-defined genetic 
forms have been recognized.  Clinical presentation is highly variable, ranging 
from various patterns of microbial susceptibility to allergy, lymphoproliferation 
or autoimmune manifestation the most of these syndromes are monogenic and 
lead to defects in any aspect of the immune response.  Along with typical form 
of these syndromes there are several disease in which the clinical signs are less 
suggestive of immunodeficiency.  In these form it is very difficult make the 
diagnosis.  In the course of this PhD program we try to better clarify for some of 
these complex phenotypes the correlation between genotype and phenotype, 
identify the biochemical biomarkers that make possible the diagnosis and 
eventually clarify the pathogenesis mechanism of these syndromes.   
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